Introduction The use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with a reduced risk of several cancers. Evidence for NSAIDs preventing head and neck cancer (HNC) is inconclusive. We conducted a prospective cohort study to examine the association between NSAID use and HNC risk.
Methods Using data from the National Cancer Institute (NCI) Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, we examined the association between aspirin / NSAID use and HNC incidence among 142 034 men and women aged 55–74 years. Information regarding regular use and frequency of use of aspirin and NSAIDs over the last 12 months was reported at enrolment. (1993–2001). Individuals were followed-up until 2006. HRs and 95% CIs were calculated using multivariable cox proportional hazards regression with adjustment for potential confounders including tobacco use, gender, body mass index and age.
Results Over the follow-up period 316 individuals were diagnosed with HNC. Regular aspirin use, compared to non-use, was associated with a significantly reduced incidence of HNC (Adjusted HR 0.78; 95% CI 0.62 to 0.98). No association was observed with regular NSAID use, compared to non-use, and HNC incidence (adjusted HR 0.99, 95% CI 0.76 to 1.28).
Conclusions Our study suggests that aspirin may have potential as a chemopreventative agent for HNC however further investigation is warranted.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.